Scarica l'app Stockscreener
120.87
0.02%
0.03
Dopo l'orario di chiusura:
120.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$120.84
Aprire:
$120.37
Volume 24 ore:
6.26M
Relative Volume:
0.54
Capitalizzazione di mercato:
$298.84B
Reddito:
$64.93B
Utile/perdita netta:
$18.26B
Rapporto P/E:
16.61
EPS:
7.2751
Flusso di cassa netto:
$12.36B
1 W Prestazione:
+1.63%
1M Prestazione:
-0.44%
6M Prestazione:
+35.04%
1 anno Prestazione:
+39.57%
Intervallo 1D:
$119.22
$121.65
Intervallo di 1 settimana:
$117.22
$122.19
Portata 52W:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-02-13 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-10-13 | Ripresa | Citigroup | Neutral |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Nvwm LLC Acquires 31,854 Shares of Merck & Co., Inc. $MRK - MarketBeat
JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co - MarketBeat
Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK - MarketBeat
SS&H Financial Advisors Inc. Acquires 12,200 Shares of Merck & Co., Inc. $MRK - MarketBeat
SteelPeak Wealth LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Quintet Private Bank Europe S.A. - MarketBeat
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Merck & Co., Inc. stock: Steady performer amid healthcare shifts - AD HOC NEWS
Erste Group Initiates Merck & Co(MRK.US) With Hold Rating - Moomoo
West Branch Capital LLC Sells 15,875 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock: Strong margins amid shifting pharma winds - ad-hoc-news.de
Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC - MarketBeat
16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Aberdeen Group plc - MarketBeat
Merck & Co., Inc. stock: A cornerstone of pharmaceutical innovation and dividend reliability for lon - AD HOC NEWS
FinancialContentMerck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer - markets.financialcontent.com
Merck Just Made a Big Bet on a New Cancer Growth Engine - Investing.com
Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration - ROI-NJ
Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration - MarketScreener
Merck & Co Inc (MEX:MRK) Stock Price, Trades & News - gurufocus.com
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investiga - PharmiWeb.com
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study - Insider Monkey
Merck's (MRK) Keytruda Gains Fast Track Status in Colorectal Can - gurufocus.com
Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co - MarketScreener
Merck wins EU nod for Keytruda combo in ovarian cancer (MRK) - Seeking Alpha
Merck (MRK) Gains EU Approval for Keytruda Regimen in Ovarian Ca - GuruFocus
Merck (MRK) Advances MK-8748 Trial for Eye Disease Treatment - GuruFocus
Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer - MarketScreener
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - Business Wire
Tema Etfs LLC Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Bank Pictet & Cie Europe AG Lowers Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Banque Pictet & Cie SA - MarketBeat
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 - Insider Monkey
Startup Infinimmune sees close to $1 billion, validation in big Merck drug dealSan Francisco Business Times - The Business Journals
Merck (NYSE: MRK) director receives new cash-settled phantom stock grant - Stock Titan
Merck (MRK) director Glocer granted 405 phantom stock units, holds 5,100 shares - Stock Titan
Merck (NYSE: MRK) director granted new phantom stock units - Stock Titan
Merck & Co deal worth up to $838 million to Infinimmune - The Pharma Letter
What's Going On With Merck Stock Wednesday?Merck & Co (NYSE:MRK) - Benzinga
Vaughan Nelson Investment Management L.P. Sells 11,515 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Highline Wealth Partners LLC - MarketBeat
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 - Business Wire
Nisa Investment Advisors LLC Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Moody Lynn & Lieberson LLC - MarketBeat
Shrier Wealth Management LLC Buys New Position in Merck & Co., Inc. $MRK - MarketBeat
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - Yahoo Finance
Econ Financial Services Corp Sells 8,757 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):